MedTrace Logo

A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD

NCT00242333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2006-05-16

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

DRUG

AD 237

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Sosei

    lead INDUSTRY

Principal Investigators

  • Robert G Tansley, MD · Arakis Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31

Countries

  • Bulgaria
  • Hungary
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242333 on ClinicalTrials.gov